FYI From Human Genome Sciences: GSK Initiates Darapladib Phase 3 Development Program (Medical News Today)
Neuralstem, Inc. (NYSE Alternext US: CUR) announced this morning that it has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to begin a clinical trial to treat amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease).

VITROS(R) 3600 Immunodiagnostic System for Laboratory Diagnostics Receives 510(k) Clearance from the FDA (PR Newswire via Yahoo! Finance)
High-Volume System Combines Accuracy and Efficiency with Broad Menu of Routine and Infectious Disease Immunoassays -